Specification :

Sitagliptin phosphate ( diabetes treatment drug CAS: 486460-32-6)
Chemicalname: ( 3R) -3-Amino-1-[ 3-( trifluoromethyl) -5, 6, 7, 8-tetrahydro-1, 2, 4-triazolo[ 4, 3-a] pyrazin-7-yl] -4-( 2, 4, 5-trifluorophenyl) butan-1-one
Molecular formula: C16H15F6N5O
Molecular Weight: 407.32
Merck' s diabetes treatment drug Sitagliptin Phosphate, known as commodity JANUVIA ( TM) , in August 8, 2006 first allowed to market in Mexico and in October 17, 2006 in the United States to obtain FDA approval, is the first approved Listed on the Second-peptide peptidase ( DPP-IV) inhibitors
Usage: Type 2 diabetes treatment drug
Aniracetam ( Central stimulant Drug CAS: 72432-10-1)
CAS: 72432-10-1
English alias: 1 - ( 4-methoxybenzoyl) -2-pyrrolidinone
Formula: C12H13NO3
Molecular Weight: 219.24
Drug Category: Central stimulant
Indications: suitable for medium and memory impairment in elderly and cerebrovascular disease after the memory impairment
Pharmaco: improve brain function, the ? aminobutyric acid ( GABA) derivatives of the ring. This product through the selective blood-brain barrier in the role of the central nervous system. Animal experiments to prove: The goods on normal learning and memory in rats to identify the process again a good role, to fight against hypoxia-induced memory impairment, to provide measurable improvements to some of the causes of memory impairment